Filing Flows › Arcutis Biotherapeutics (ARQT) › Q3 2026 › vs Q2 2026
Arcutis Biotherapeutics (ARQT) Q3 2026 vs Q2 2026 (quarter over quarter)
Arcutis Biotherapeutics's revenue rose $14.1M (+11%) from $130M in Q2 2026 to $144M in Q3 2026. The biggest changes: ZORYVE foam +$7.8M (+12%); ZORYVE cream 0.15% +$3.0M (+13%); ZORYVE cream 0.3% +$2.5M (+7%). Operating margin 6.6% against 12.7% (-6.1 pts).
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 6.6% | 12.7% | -6.1 pts |
| Net margin | 6.1% | 11.6% | -5.4 pts |
| Free cash flow margin | 13.1% | 9.6% | +3.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| ZORYVE foam | $75.1M | $67.4M | $7.8M | +12% |
| ZORYVE cream 0.3% | $37.8M | $35.3M | $2.5M | +7% |
| ZORYVE cream 0.15% | $27.3M | $24.2M | $3.0M | +13% |
| ZORYVE cream 0.05% | $3.7M | $2.9M | $814K | +28% |
| Revenue | $144M | $130M | $14.1M | +11% |
| Operating profit | $9.4M | $16.4M | −$7.0M | -43% |
| Costs & expenses | $134M | $113M | $21.1M | +19% |
| Pre-tax earnings | $9.0M | $15.1M | −$6.1M | -41% |
| Other expense, net | $440K | $1.3M | −$844K | -66% |
| Cost of revenue | $12.5M | $10.9M | $1.5M | +14% |
| Research & development | $22.4M | $20.4M | $2.1M | +10% |
| SG&A | $99.6M | $82.1M | $17.5M | +21% |
| Net earnings | $8.8M | $15.0M | −$6.2M | -41% |
| Income tax | $195K | $136K | $59K | +43% |
| Share-based compensation | $12.4M | $12.8M | −$404K | -3% |
| Working capital & other | $2.3M | $15.1M | −$12.9M | -85% |
| Operating cash flow | $18.9M | $12.6M | $6.3M | +50% |
| Free cash flow (OCF − capex) | $18.8M | $12.5M | $6.3M | +51% |
| Capital expenditures | $97K | $158K | −$61K | -39% |
Questions
How much did Arcutis Biotherapeutics's revenue grow quarter over quarter in Q3 2026?
Arcutis Biotherapeutics's revenue rose $14.1M (+11%) from $130M in Q2 2026 to $144M in Q3 2026.
What drove Arcutis Biotherapeutics's revenue change in Q3 2026?
ZORYVE foam +$7.8M (+12%); ZORYVE cream 0.15% +$3.0M (+13%); ZORYVE cream 0.3% +$2.5M (+7%).